BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 8700224)

  • 1. Cdc25 cell-cycle phosphatase as a target of c-myc.
    Galaktionov K; Chen X; Beach D
    Nature; 1996 Aug; 382(6591):511-7. PubMed ID: 8700224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
    Wang Z; Ge L; Wang M; Carr BI
    J Cell Physiol; 2006 Jul; 208(1):133-40. PubMed ID: 16596619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
    Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
    Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
    Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
    Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
    Marcotte R; Chen JM; Huard S; Wang E
    J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle: on target with Myc.
    Zörnig M; Evan GI
    Curr Biol; 1996 Dec; 6(12):1553-6. PubMed ID: 8994810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of Myc targets in c-myc and N-myc induced human tumors.
    Ben-Yosef T; Yanuka O; Halle D; Benvenisty N
    Oncogene; 1998 Jul; 17(2):165-71. PubMed ID: 9674700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells.
    Wang Q; Zhang H; Kajino K; Greene MI
    Oncogene; 1998 Oct; 17(15):1939-48. PubMed ID: 9788437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bax is a transcriptional target and mediator of c-myc-induced apoptosis.
    Mitchell KO; Ricci MS; Miyashita T; Dicker DT; Jin Z; Reed JC; El-Deiry WS
    Cancer Res; 2000 Nov; 60(22):6318-25. PubMed ID: 11103792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation.
    Greenberg RA; O'Hagan RC; Deng H; Xiao Q; Hann SR; Adams RR; Lichtsteiner S; Chin L; Morin GB; DePinho RA
    Oncogene; 1999 Feb; 18(5):1219-26. PubMed ID: 10022128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
    Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
    Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Myc-regulated microRNAs modulate E2F1 expression.
    O'Donnell KA; Wentzel EA; Zeller KI; Dang CV; Mendell JT
    Nature; 2005 Jun; 435(7043):839-43. PubMed ID: 15944709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-phase induction by adenovirus E1A requires activation of cdc25a tyrosine phosphatase.
    Spitkovsky D; Jansen-Dürr P; Karsenti E; Hoffman I
    Oncogene; 1996 Jun; 12(12):2549-54. PubMed ID: 8700513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel c-Myc protein interactor, JPO2, with transforming activity in medulloblastoma cells.
    Huang A; Ho CS; Ponzielli R; Barsyte-Lovejoy D; Bouffet E; Picard D; Hawkins CE; Penn LZ
    Cancer Res; 2005 Jul; 65(13):5607-19. PubMed ID: 15994933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Function of the c-Myc oncogenic transcription factor.
    Dang CV; Resar LM; Emison E; Kim S; Li Q; Prescott JE; Wonsey D; Zeller K
    Exp Cell Res; 1999 Nov; 253(1):63-77. PubMed ID: 10579912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product.
    Luo Q; Li J; Cenkci B; Kretzner L
    Oncogene; 2004 Feb; 23(5):1088-97. PubMed ID: 14716294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas.
    Hernández S; Hernández L; Beà S; Cazorla M; Fernández PL; Nadal A; Muntané J; Mallofré C; Montserrat E; Cardesa A; Campo E
    Cancer Res; 1998 Apr; 58(8):1762-7. PubMed ID: 9563496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
    Cosgrave N; Hill AD; Young LS
    J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformation.
    Dolnikov A; Millington M; Sun LQ; Symonds G
    Cancer Gene Ther; 2000 Nov; 7(11):1491-503. PubMed ID: 11129291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.